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Introduction: Basaloid squamous cell carcinoma is a rare and aggressive variant of squamous cell carcinoma.
Basaloid squamous cell carcinoma is mostly seen in the upper aerodigestive tract and has a propensity for lymph
node spread and systemic metastases. Various treatment modalities have been reported, including surgical excision
supplemented with radiotherapy/adjuvant chemotherapy. To the best of our knowledge, treatment of nasal basaloid
squamous cell carcinoma with proton beam therapy and cisplatin has not been described in the literature.
Case presentation: We report the case of a 56-year-old Japanese man with locally invasive basaloid squamous cell
carcinoma in his right nasal cavity with invasion of the orbit, paranasal sinus, and buccal subcutaneous tissue. He
underwent proton beam therapy concurrent with cisplatin. Acute and late side effects did not exceed grade 3. At
24-month follow up, he remains in complete remission.
Conclusion: Proton beam therapy concurrent with cisplatin may be one choice for locally invasive basaloid squamous
cell carcinoma.
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The histological characteristics of basaloid squamous cell
carcinoma (BSCC) were first described by Wain et al. in
1986 [1]. BSCC is a rare and aggressive variant of squa-
mous cell carcinoma (SCC). BSCC is mostly seen in the
upper aerodigestive tract, including the oral cavity, larynx,
and hypopharynx [2-4]. BSCC has a propensity for nodal
spread and systemic metastases. Various treatment modal-
ities have been reported, including surgical excision sup-
plemented with radiotherapy/adjuvant chemotherapy [2-7].
There is no established consensus on treatment because of
the limited number of cases of BSCC. We report the case
of a patient with locally invasive BSCC of the nasal cavity
who was treated with proton beam therapy (PBT) concur-
rent with cisplatin (CDDP).* Correspondence: shigerad@staff.kanazawa-u.ac.jp
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A 56-year-old Japanese man presented with a 1-month his-
tory of right nasal obstruction and ipsilateral slight pain in
the buccal region. On examination, his right nasal cavity
was filled with a hemorrhagic nasal polyp, and there was
reddening and swelling of his skin in the right buccal re-
gion, and narrowing of the choroid fissure. He was admit-
ted to our hospital. Computed tomography and magnetic
resonance imaging revealed a tumor mass filling his right
nasal cavity and infiltrating the right maxillary sinus, eth-
moid sinus, frontal sinus, orbital floor, and orbital medial
wall with erosion of bone and subcutaneous fat in the right
buccal region. The tumor size was 57×52×34mm (Figures 1
and 2). Fluorine-18 fluorodeoxyglucose (FDG) positron
emission tomography (PET) showed uptake of FDG by the
tumor. The maximum standard uptake values of the tumor
obtained during FDG-PET were 14.9 at early imaging
(60 minutes; Figure 3). On histopathological examination,
the tumor grew as cords with peripheral palisading andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Figure 1 Contrast-enhanced computed tomography scans. (a) Contrast-enhanced computed tomography reveals a right nasal cavity tumor with
invasion of the right maxillary sinus and frontal sinus (yellow circle), (b) with invasion of the right orbit and destruction of the medial orbital wall (yellow circle).
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ratio. Cords of invasive basaloid cells positive for cytokera-
tin 14 and negative for chromogranin A and B-cell lymph-
oma 2 were seen (Figure 4). A diagnosis of BSCC in his
right nasal cavity, stage III, T3N0M0 was made (Inter-
national Union Against Cancer, 7th edition).Figure 2 Magnetic resonance imaging scans. Magnetic resonance imag
the right maxillary sinus, ethmoid sinus, and subcutaneous fat in the rightThe risks and benefits of surgery and chemoradiother-
apy were explained to the patient. He inquired about
PBT. We explained the risks and benefits of PBT and its
available alternatives. He decided to undergo PBT and
chemotherapy. The treatment plan was decided after in-
formed consent for PBT with concurrent chemotherapy.ing reveals a tumor mass filling the right nasal cavity and infiltrating
buccal region.
Figure 3 Fluorine-18 fluorodeoxyglucose-positron emission tomography scans. (a) Fluorine-18 fluorodeoxyglucose-positron emission
tomography showed uptake of fluorine-18 fluorodeoxyglucose by the tumor (yellow circle). The maximum standard uptake values of the tumor
obtained during fluorine-18 fluorodeoxyglucose-positron emission tomography were 14.9 at early imaging (60 minutes). (b) Positron emission
tomography 2 years after completing proton beam therapy. There is no evidence of tumor recurrence.
Takamatsu et al. Journal of Medical Case Reports 2014, 8:123 Page 3 of 5
http://www.jmedicalcasereports.com/content/8/1/123The chemotherapy was single-agent, high-dose CDDP
(100mg/m2) on days 1, 22, and 43 during PBT. He received
the three courses of chemotherapy along with PBTas sched-
uled. Assuming a relative biological effectiveness of 1.1, the
total dose of PBT was 70 cobalt Gy equivalent (CGE) in two
CGE once-daily fractions, 5 days per week, for 7 weeks.Figure 4 Histological and immunohistochemical images. (a), (b) Biopsy
peripheral palisading. The tumor had hyperchromatic nuclei with a high n
Immunohistochemical stains of the tumor were positive for cytokeratAcute and late side effects did not exceed grade 3 ac-
cording to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events version 4.0. The
early side effects of oral mucositis, dermatitis, and super-
ficial keratitis of his right eye were grade 2, and hemato-
toxicity was grade 1. The late side effect of superficialspecimen of nasal tumor shows cords of invasive basaloid cells with
uclear-to-cytoplasmic ratio (hematoxylin and eosin stain). (c)
in 14.
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sion in his right eye caused by retinopathy or optic nerve
disorder was grade 1. FDG-PET after treatment showed
no evidence of recurrence (Figure 4). He remains in
complete remission (CR) 2 years after treatment.
Discussion
BSCC in the nasal cavity and paranasal sinuses is very rare,
with only 29 reported cases in the English language litera-
ture [2-6]. For advanced head and neck cancer, chemora-
diotherapy is the gold standard of treatment [8,9]. In
advanced BSCC, the standard of care has not been estab-
lished. Our regimen used a CDDP single agent, the same
as that used by Adelstein et al. [10]. Combination chemo-
therapy with CDDP and 5-fluorouracil (5-FU) is an ef-
fective regimen for head and neck cancer [8]. In 5-FU
treatment, the 5-FU-related enzyme activities affect the
clinical response to chemotherapy: thymidylate synthase
(TS) [11]. Takemura et al. compared the 5-FU-related en-
zyme activity between esophageal BSCC and SCC. The TS
activity was significantly higher in BSCC, suggesting that
BSCC may have more resistance to 5-FU than SCC in the
esophagus [12]. Extrapolating from their results, CDDP
single-agent chemotherapy in nasal BSCC may be more
effective than combination chemotherapy.
To the best of our knowledge, nasal BSCC treated with
PBT has not been described in the literature. PBT has
the ability to precisely localize the radiation dose, facili-
tating significant sparing of normal tissues in head and
neck lesions [13]. The use of this feature helps mitigate
the side effects of conventional radiotherapy occurring
with concurrent chemotherapy.
Good local control was achieved in this case, suggesting
that PBT might allow the avoidance of surgery. Given the
high incidence of distant metastasis, concurrent or adju-
vant chemotherapy is most probably necessary, especially
for progressive lesions. In locally progressive BSCC with-
out distant lesions, PBT concurrent with CDDP may be
considered one method of treatment. It is difficult to es-
tablish high-level evidence because of the rarity of nasal
BSCC, but further studies are needed to determine the op-
timal treatment for BSCC.
Conclusions
We report a case of locally invasive nasal BSCC treated
with PBT concurrent with CDDP. This case continues to
show CR at 2-year follow-up with few side effects. Fur-
ther studies are required to achieve a consensus regard-
ing BSCC treatment, but the treatment plan adopted in
our case may be one option for locally invasive BSCC.
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